Targets › DNMT
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2028.
DNA methyltransferase that methylates CpG residues. Preferentially methylates hemimethylated DNA. Associates with DNA replication sites in S phase maintaining the methylation pattern in the newly synthesized strand, that is essential for epigenetic inheritance. (UniProt, P26358)
Open in Phaseline: the race on DNMT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | 5-aza-4'-thio-2'-deoxycytidine (Aza-TdC) DNA methyltransferase inhibitor; nucleoside analog that inhibits methylation-mediated gene | DNMT | Phase 1 | Neoplasms | Sep 2028 |
Neoplasms (1)
small molecule (1)
National Cancer Institute (NCI) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.